Medpace General Counsel & Corp. Secy. Sold Shares Worth Over $859K

Medpace Holdings' General Counsel Stephen P. Ewald sold 1,245 shares at $690 each, totaling $859,050. He now directly owns 19,098 shares, according to an SEC Form 4 filing.

Original reporting
Published Nov 2, 2026, 11:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 11:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Medpace General Counsel & Corp. Secy. Sold Shares Worth Over $859K — source image
Decision brief

The 30-second read

Low
01

Why it matters

The disclosed sale reduces insider ownership, which can be interpreted as a slight negative signal.

02

Market read

Small insider sell; limited immediate market impact.

03

What to watch

Potential tax planning or personal liquidity needs driving the sale.

Relevance 4/10Novelty 4/10Timing: after-hours

Background

Form 4 insider transaction disclosures provide transparency on executive holdings.

Market effects

None significant for the broader healthcare services sector.

Limited to US markets where Medpace trades.

Minimal.

Counterpoint

The sale could be unrelated to company fundamentals and may not affect price.

Key entities

  • Medpace Holdings, Inc.

    US-listed clinical research organization (NASDAQ: MPC).

  • Stephen P. Ewald

    General Counsel & Corporate Secretary of Medpace.

Related articles

$MEDPMedAI 8/10

MEDP Q3 deep dive: bookings strength drives growth, margin expansion continues

MEDP reported Q3 revenue of $716M, beating estimates, with EPS of $4.84 and adjusted EBITDA of $172.1M. The company reconfirmed full-year revenue guidance of $2.85B and raised EPS guidance to $18.15. Growth was driven by strong bookings in oncology research and margin expansion from a favorable project mix. Management highlighted stable competition, low turnover, and sustained bookings momentum, but noted project cancellations as a watchpoint.

$MEDPMedAI 8/10

Medpace 3Q 2026: Revenue $716M, EPS $4.84— 10-Q Summary

Medpace Holdings reported Q3 2026 revenue of $716M, up 8.5% YoY, with net income rising 23.7% to $137.46M and EPS increasing 25.4% to $4.84. Growth was driven by Metabolic, Oncology, and CNS services. Nine-month revenue grew 16.9%, net awards reached $873.4M, and backlog increased 5.6% YoY to $3.17B. The company plans organic growth and selective acquisitions.

$MEDPHighAI 8/10

Medpace (MEDP) Q3 2026 Earnings Call Transcript

Medpace (MEDP) reported Q3 2026 revenue of $716M, up 8.5% YoY, with EBITDA of $172.1M (up 16%) and net income of $137.5M (up 23.7%). Guidance raised: revenue $2.835B-$2.855B (12-12.8% growth), EBITDA $638M-$652M (14.4-16.9% growth), EPS $17.97-$18.32. Board approved $1B share repurchase program. Net new business awards up 10.6% QoQ.

$MEDPMed

Medpace Q3 Earnings Call Highlights

Medpace reported a 10.6% year-over-year increase in net new business awards to $873.4 million in Q3, with a total 12-month backlog of $3.02 billion. Ending backlog was $3.2 billion, up 5.6% year-over-year. The company expects $1.99 billion of backlog to convert into revenue over the next year. Management noted shifts in therapeutic mix and strong pending opportunities. Medpace plans to provide 2027 guidance in February, with fourth-quarter awards and cancellations influencing the outlook.

$MEDPHighAI 8/10

Medpace Q3 2026 slides: record awards fuel profit beat, guidance raised

Medpace Holdings (NASDAQ:MEDP) reported Q3 2026 revenue of $716.0M, up 8.5% YoY, and adjusted earnings of $4.84 per share, exceeding estimates. Net income rose 23.7% to $137.5M, with EBITDA margin widening to 24.0%. The company raised its full-year guidance, citing record new business awards and strong profitability trends. Shares traded near $659.37, close to their 52-week high.